Co­herus sells San­doz its Lu­cen­tis biosim­i­lar for $170M to fo­cus on on­col­o­gy as­sets 

Co­herus Bio­Sciences is sell­ing its FDA-ap­proved oph­thal­mol­o­gy biosim­i­lar Cimer­li — a copy­cat ver­sion of Roche’s Lu­cen­tis — to San­doz for $170 mil­lion in cash to fo­cus on its on­col­o­gy pipeline.

“This di­vesti­ture will al­low us to re­duce our head­count and over­head costs, en­hanc­ing our sus­tain­able and grow­ing on­col­o­gy busi­ness,” Co­herus CEO Den­ny Lan­fear said in a re­lease on Mon­day.

The di­vesti­ture, which marks San­doz’s first deal since spin­ning out of No­var­tis, is ex­pect­ed to close in the first half of the year and in­cludes Cimer­li’s bi­o­log­ics li­cense ap­pli­ca­tion, com­mer­cial soft­ware, as well as the drug’s sales and field re­im­burse­ment teams. San­doz will al­so get the “sup­port­ing com­mer­cial in­fra­struc­ture” of Cimer­li, with an ad­di­tion­al pay­ment for oth­er prod­uct in­ven­to­ry to fol­low.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER